论文部分内容阅读
研究证明n NOD2、ATG16L1、IL-23R、TNFAIP3、FCGR3A基因的多态性不仅和炎症性肠病（IBD）的发病有关，而且与抗肿瘤坏死因子（TNF）-α单克隆抗体治疗效果有关。本文就这5种基因多态性对抗TNF-α单克隆抗体治疗IBD疗效的预测作用进行综述，为更好地指导临床用药提供依据。n “,”The polymorphisms of n NOD2, n ATG16L1, n IL-23R, n TNFAIP3 and n FCGR3A genes are not only related to the pathogenesis of inflammatory bowel disease, but also related to the therapeutic effect of anti-tumor necrosis factor-α (anti-TNF-α) monoclonal antibody. This article reviews the predictive effect of these five gene polymorphisms in the efficacy of anti-TNF-α monoclonal antibodies for the treatment of inflammatory bowel disease and provides evidences for better guiding the clinical drug use.n